In addition to a steep slide in the company's share price, Raymond James lowered its rating for Cepheid's stock to Market Perform.
BTIG and Mizuho downgraded Illumina's stock after it preannounced third quarter revenue estimates that fell short of analysts' average expectations.
The investment bank also cited challenges for Illumina in penetrating the clinical diagnostics markets and driving physician adoption of its tests.
The investment bank downgraded Illumina to a Neutral rating after the company missed the consensus Wall Street estimate for its revenues.
Analyst William Quirk remained bullish on the firm but downgraded the shares based on their valuation, which he said have little room to grow.
Even as Hologic enters the "sweet spot" in the adoption cycle for its 3D tomography tests, Evercore said there is "limited upside" to the company's current share price.
The investment bank noted the potential of Alere's new MDx platforms, but said that Quest's potential could suffer in comparison to its competitor LabCorp.
The downgrade follows Roche's proposed bid to acquire a majority stake in the company.
The investment bank downgraded Meridian Bioscience from a prior Market Perform rating, noting challenges to its molecular diagnostics business.
The investment bank expressed doubts about Qiagen's GeneReader NGS platform, among other things, and Bruker's mixed recent record on improving its operations.
Bioethicists disagree with a research team's decision to allow the return of risk results for adult-onset conditions from a newborn sequencing project, according to Reuters.
Alterations to particular gene may enable the Quechua of Peru to better tolerate high-altitude life, Ars Technica reports.
Nature News reports that additional South Korean researchers have included the names of children on scientific papers when they did not contribute to the work.
In PLOS this week: statistical approach to prioritize rare variant searches, gene expression alterations in chronic obstructive pulmonary disease, and more.